• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harpoon Therapeutics Inc (NQ: HARP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Harpoon Therapeutics Inc

< Previous 1 2 Next >
Harpoon Therapeutics Inc. (NASDAQ: HARP) Records 52-Week High Thursday Morning
February 22, 2024
Via Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
January 10, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
Harpoon Therapeutics Inc. (NASDAQ: HARP) Near the Top of Equities by Percentage Gain on 1/8
January 08, 2024
Via Investor Brand Network
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
Exposures US Equities
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
January 08, 2024
From Halper Sadeh LLC
Via Business Wire
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
January 08, 2024
From Merck & Co., Inc.
Via Business Wire
Harpoon Therapeutics Strengthens Leadership Team
December 26, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
December 19, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
December 11, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Up to $150 Million Private Placement
October 23, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
October 21, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Inc. (NASDAQ: HARP) Leading the Way in Wednesday Trading Based on Percentage Gain
October 18, 2023
Via Investor Brand Network
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
October 16, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
October 09, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
September 28, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
September 15, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
September 13, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
September 06, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
September 05, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 05, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
August 03, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
August 01, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From Harpoon Therapeutics
Via GlobeNewswire
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
April 18, 2023
From Harpoon Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap